Immune Pharmaceuticals Inc (NASDAQ:IMNP) was the recipient of a large growth in short interest in April. As of April 28th, there was short interest totalling 750,273 shares, a growth of 35.8% from the April 13th total of 552,499 shares. Approximately 8.5% of the company’s stock are short sold. Based on an average daily trading volume, of 2,183,226 shares, the days-to-cover ratio is currently 0.3 days.

Shares of Immune Pharmaceuticals (NASDAQ:IMNP) opened at 2.66 on Friday. The company’s market capitalization is $17.46 million. Immune Pharmaceuticals has a 12 month low of $2.14 and a 12 month high of $12.80. The firm’s 50-day moving average is $1.63 and its 200 day moving average is $0.56.

A hedge fund recently raised its stake in Immune Pharmaceuticals stock. Vanguard Group Inc. boosted its position in shares of Immune Pharmaceuticals Inc (NASDAQ:IMNP) by 25.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,983,017 shares of the biopharmaceutical company’s stock after buying an additional 1,001,138 shares during the period. Vanguard Group Inc. owned 75.91% of Immune Pharmaceuticals worth $728,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.18% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/13/immune-pharmaceuticals-inc-imnp-short-interest-up-35-8-in-april.html.

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.

5 Day Chart for NASDAQ:IMNP

Receive News & Ratings for Immune Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.